• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Concord Biotech: Stock Market’s New Biotech entrant ready with IPO
  • National Research Foundation (NRF): facing support and resistance from scientific communities! Why?
  • Biodiversity- preserve or perish
  • Dr Rajesh Gokhale assumes charge as Secretary of Department of Science and Technology
  • Advancing allergy detection and management in India: A pathway to improved health
  • Gujarat govt signs MOUs with 15 companies for ₹2000 cr in a single day
  • Pune biotech firm announces cheaper drug for colorectal cancer
  • Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Processors
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    May 22, 2023

    Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society

    July 26, 2022

    We are making best hygiene solutions through Biotech applications: Dr Rachna Dave, founder MicroGO

    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Expert Views: Stem Cells as Clinical and Research Tools For COVID-19

Expert Views: Stem Cells as Clinical and Research Tools For COVID-19

0
By Biotech Express on May 18, 2020 Articles, Articles- Guestorials, SARS- CoV2 & COVID-19 Updates

by S. Dravida, PhD
Founder and CEO, Transcell Biologics

World Health Organization (WHO) has named SARS-CoV2 (a new format of corona virus) as COVID-19 while declaring it as causative agent of the pandemic outbreak in 2020 with roots from China. According to a recent publication of the International Society for Stem Cell Research (ISSCR), currently, there are no approved stem cell-based approaches neither for prevention nor treatment of COVID-19 infection. Mesenchymal stem cells (MSCs) are being researched and trialed as one of the therapeutic tools in the treatment of COVID19. The hypothesis on which MSCs are being trialed is that this particular stem cell type opposes viral infection due to the secretion of specific cytokines by them. These ancillary secretory components are present in MSCs in their intrinsic forte and so they survive even if they are transplanted into a patient with a confirmed COVID-19 infection.

 

About Author  

S Dravida leads the team and collaborations responsible for discovering druggable formulations across therapeutic areas and platforms. Her role requires converging and executing both laboratory, clinical research programs across touch points. Her Past Affiliations include University of North Carolina, Ottawa Health Research Institute and Center for Cellular and Molecular Biology, Hyderabad Eye Research Foundation. Expertise: Adult stem cell technologies, Predictive platform development and screening, Primary cells, Tumorospheres, Low throughput and High throughput platform technologies, Cancer progenitor cells, Repository of patient sourced screening platforms, Cell based readouts, Drug discovery, pre-discovery process etc.

 

 

COVID-19 is shown to trigger a destroying immune overreaction in the body while the immune system produces large amounts of inflammatory factors, causing a cytokine storm that includes an overproduction of immune cells and cytokines. MSCs are postulated to prevent the storm release of cytokines by the immune system and stimulate endogenous repair by reparative properties owing to their stemness. Typically, after intravenous injection, portion of the injected MSCs entangle in the lung, which in otherwise systemic infusion is perceived as a limitation, while it is a blessing in disguise for COVID-19 patients that could positively influence the recovery in the pulmonary microenvironment by way of protecting alveolar epithelial cells, intercepting pulmonary fibrosis, and ultimately curing lung dysfunction and pneumonia caused by the virus.

Adult stem cells especially MSCs can be handy to mimic the human host environment when modeling viral pathogenesis invitro. Noroviruses, rotaviruses, enteroviruses, adenoviruses, zika virus and many other viruses were studied by infecting stem cell cultures invitro while genome-wide analysis of host-virus crosstalk, identification of host factors critical for viral pathogenesis, and the study of viral pathogens are some of the lab based research findings supporting the discovery and development of solutions to diagnose and cure viral diseases. Human biological discards sourced MSCs could be an ideal stem cell type for invitro infection studies with COVID-19 strain while addressing the otherwise known challenges dealing with biopsies, availability, ethics etc.

MSCs type has attracted attention to be considered as therapeutic tool for COVID-19 infection due to source availability, their high proliferation rate supporting in culturing in the labs, low invasive procedure when being injected, and with no ethical issues. As MSCs can be stored for repetitive therapeutic usage, biobanks could play a quintessential role in the supply with safety and efficacy of MSCs documented in several clinical trials.

Pathological microenvironment induced by viral infections in cell cultures contribute tremendously to a researcher’s work on host-virus interactions. If the cell cultures are harvested from human system, they become an amazing alternative invitro systems that accurately re-create in vivo human physiology that can support the study of viral pathogenesis.

About Transtoxbio
Transtoxbio (www.transtoxbio.com) is a portfolio with all new league of human biological discards sourced (ethically immuned) primary progenitor cell based platforms for specialty next generation invitro applications in preclinical basic and translational research. Primary stem cells are amenable to any research specific modelling and are cost-effective in the scheme of operations with relevant human specific read outs obtained as experimental end points.

Reference:
1. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future [published online ahead of print, 2020 Apr 13]. Stem Cell Rev Rep. 2020;1‐7. doi:10.1007/s12015-020-09973-w
2. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging and disease 2020, Vol. 11. Issue (2) : 216-228 DOI: 10.14336/AD.2020.0228

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

National Research Foundation (NRF): facing support and resistance from scientific communities! Why?

Biodiversity- preserve or perish

Advancing allergy detection and management in India: A pathway to improved health

Leave A Reply Cancel Reply

Current Issue – July 2023
Upcoming Event

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Concord Biotech: Stock Market’s New Biotech entrant ready with IPO July 31, 2023
  • National Research Foundation (NRF): facing support and resistance from scientific communities! Why? July 25, 2023
  • Biodiversity- preserve or perish July 24, 2023
  • Dr Rajesh Gokhale assumes charge as Secretary of Department of Science and Technology July 23, 2023
  • Advancing allergy detection and management in India: A pathway to improved health July 23, 2023
  • Gujarat govt signs MOUs with 15 companies for ₹2000 cr in a single day July 22, 2023
  • Pune biotech firm announces cheaper drug for colorectal cancer July 21, 2023
  • Ambiq Propels Remote Healthcare Monitoring Sector Growth with New Ultra-Low Processors July 20, 2023
  • BMJ Open retracted a diabetes paper because it was funded by tobacco company July 19, 2023
  • Indian scientist made First Marwari horse foal through Embryo transfer technology July 12, 2023
  • Prof Rajeev Varshney becomes the 4th Indian Agricultural Scientist to be elected as Fellow of the Royal Society May 22, 2023
  • FABA holds Conference on Antimicrobial Resistance Stewardship Series May 22, 2023
  • COVID no longer a global health emergency, WHO says May 18, 2023
  • Chemist in India loses seven papers of biology, blames outsourcing of images May 17, 2023
  • Indian Research scholars express frustration over DST’s tweet, plan stir May 16, 2023
  • BioAsia 2023 to be held in February 24-26 in Telangana, India January 10, 2023
  • Praj Industries and ESIIC partner to further bioeconomy in Egypt November 10, 2022
  • Who is The Real Anthony Fauci? A true Doctor, liar, pharma profiteer or a totalitarian? November 1, 2022
  • Guestorial: MALNUTRITION ACCELERATES THE METABOLIC AGE October 31, 2022
  • Event: Australia’s biggest week in biotech kicks off in Perth October 26, 2022
  • $3 trillion growth reported for biotech sector in USA October 25, 2022
  • Event : FABA’s Whale Tank Event – “Venture Capital – Biotech Start-up Connect” September 21, 2022
  • Vaccination, Rising Deaths, And The False Narrative September 20, 2022
  • Guestorial: Genome Mapping Techniques and its Application in Aquaculture September 19, 2022
  • Bombay HC Issues Notice To Bill Gates, Serum Institute, DGCI, Others Over Plea On Alleged ‘Vaccine Death’ September 5, 2022
  • Deaths due Covid-19 vaccines should be compensated by vaccine makers: Expert hope on Kerala HC remark August 21, 2022
  • Maker of Dolo-650, pandemic’s ‘magic pill’, faces income tax searches and PIL petitions August 20, 2022
  • Anthony Fauci, Controversial US Top-doc FINALLY, To Retire By Year-end August 20, 2022
  • SII’s Cervevac: The new DCGI approved vaccine without published clinical trial results August 20, 2022
  • Pitch your Start-up to National/International Venture Capitalists – first ever opportunity provided to Bio-Start-ups by FABA August 19, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.